FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
Roth Capital downgraded RTI Biologics (NASDAQ: RTIX) from Buy to Neutral with a price target of $5.00 (from $4.50) following Q4 results.
For an analyst ratings summary and ratings history on RTI Biologics click... More

